US Edition
Teleflex Study Shows 70.5% Reduction in CLABSI with Antimicrobial CVCs
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Teleflex Study Shows 70.5% Reduction in CLABSI with Antimicrobial CVCs
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced findings from a new multinational study demonstrating the efficacy of its Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs) in reducing central line-associated bloodstream infections (CLABSIs). Conducted across 12 intensive care units in eight hospitals located in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey, the prospective cohort study included over 6,…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
